Industry
Vaccine Company, Inc.
Total Trials
3
Recruiting
0
Active
0
Completed
2
Success Rate
100.0%+13% vs avg
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
Failure Rate
0.0%
0 terminated/withdrawn out of 3 trials
Success Rate
100.0%
+13.5% vs industry average
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 2 completed trials have results
Key Signals
Enrollment Performance
Analytics
Phase 1
3(100.0%)
3Total
Phase 1(3)
Activity Timeline
Global Presence
Loading network data...
Clinical Trials (3)
Showing 3 of 3 trials
NCT07557602Phase 1Not Yet Recruiting
mRNA Vaccine Targeting Epstein-Barr Virus (EBV) in Healthy Young Adults
Role: lead
NCT05938075Phase 1Completed
Study of VXCO-100, a SARS-CoV Candidate Vaccine, in Adults in the Republic of South Africa
Role: lead
NCT05870839Phase 1Completed
Study of VXCO-100, a SARS-CoV Candidate Vaccine in Healthy Adults in the United States
Role: lead
All 3 trials loaded